Condie Carmack is a molecular immunologist who has worked with life science and diagnostic companies to develop biomarker testing equipment and reagents for cancer and cytogenetics. He led the clinical diagnostics marketing for microarray development at Agilent Technologies.
Condie helped found the Cancer Genetics Lab at Baylor College of Medicine with Marilyn Li and Federico Monzon. Prior to working in biomedical industries, he did basic research in B-cell development and invented quantitative PCR with Randy Hardy. Condie has a PhD in Experimental Pathology from the University of Utah with post-docs at Fox Chase Cancer Center in Philadelphia, PA and Medical Biology Institute in San Diego, CA.
With extensive experience in life science and diagnostic sectors, Condie has played a pivotal role in advancing biomarker testing equipment and reagents specifically for cancer and cytogenetics. His leadership in clinical diagnostics marketing was evident during his tenure at Agilent Technologies as Marketing Manager, where he focused on gene expression and copy number applications.
A testament to his commitment to the fight against cancer, Condie co-founded the Cancer Genetics Lab at Baylor College of Medicine alongside esteemed colleagues Marilyn Li and Art Beaudet. Before venturing into the biomedical industry, Condie made significant strides in basic research. Notably, working in Randy Hardy’s Lab to invent quantitative PCR, a breakthrough in B-cell development research.
Condie’s academic credentials include a PhD in Experimental Pathology from the University of Utah and a masters degree in microbiology. Further enriching his expertise, he completed post-doctoral fellowships at the renowned Fox Chase Cancer Center in Philadelphia, PA, and the Medical Biology Institute (MBI) in San Diego, CA.